A Fluorinated Supramolecular Self‐Assembled Peptide as Nanovaccine Adjuvant for Enhanced Cancer Vaccine Therapy
Small Methods · 2023-05 · 7 (5)
DOI: 10.1002/smtd.202201409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small Methods, online erschienen am 19.02.2023. Verfasst von Shaorui Jia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Frontiers Science Center for Cell Responses, State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials, Ministry of E…. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: Nankai University, Tianjin Science Fund for Distinguished Young Scholars, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Adjuvants play an important role in enhancing vaccine‐induced immune protection. Adequate cellular uptake, robust lysosomal escape, and subsequent antigen cross‐presentation are critical steps for vaccine adjuvants to effectively elicit cellular immunity. Here, a fluorinated supramolecular strategy to generate a series of peptide adjuvants by using arginine (R) and fluorinated diphenylalanine peptide (DP) is adopted. It is found that the self‐assembly ability and antigen‐binding affinity of these adjuvants increase with the number of fluorine (F) and can be regulated by R. By comparison, 4RDP(F5) shows the strongest binding affinity with model antigen ovalbumin (OVA) and the best performance in dendritic cells maturation and antigen's lysosomal escape, which contributes to the subsequent antigen cross‐presentation. As a consequence, 4RDP(F5)‐OVA nanovaccine generates a strong cellular immunity in a prophylactic OVA‐expressing EG7‐OVA lymphoma model, leading to long‐term immune memory for resisting tumor challenge. What's more, 4RDP(F5)‐OVA nanovaccine in combination with anti‐programmed cell death ligand‐1 (anti‐PD‐L1) checkpoint blockade could effectively elicit anti‐tumor immune responses and inhibit tumor growth in a therapeutic EG7‐OVA lymphoma model. Overall, this study demonstrates the simplicity and effectiveness of fluorinated supramolecular strategies for constructing adjuvants and might provide an attractive vaccine adjuvant candidate for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Frontiers Science Center for Cell Responses, State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials, Ministry of Education, and College of Life Sciences, Nankai University, Tianjin, 30…
- The Key Laboratory of Biomedical Materials, School of Life Science and Technology, Xinxiang Medical University, Xinxiang, 453003, China.
- Department of Pediatric Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
- Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
ORCID-Profile: Dan Ding
Förderung
- Nankai University
- Tianjin Science Fund for Distinguished Young Scholars
- Fundamental Research Funds for the Central Universities
- NSFC
- Tianjin Natural Science Foundation
- PhD Start-up Fund of Natural Science Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin City
Zitieren
APA
Jia, S., Ji, S., Zhao, J., Lv, Y., Wang, J., Sun, D., & Ding, D. (2023). A Fluorinated Supramolecular Self‐Assembled Peptide as Nanovaccine Adjuvant for Enhanced Cancer Vaccine Therapy. Small Methods, 7(5). https://doi.org/10.1002/smtd.202201409
Vancouver
Jia S, Ji S, Zhao J, Lv Y, Wang J, Sun D, et al. A Fluorinated Supramolecular Self‐Assembled Peptide as Nanovaccine Adjuvant for Enhanced Cancer Vaccine Therapy. Small Methods. 2023;7(5). doi:10.1002/smtd.202201409
BibTeX
@article{Jia2023,
author = {Jia, Shaorui and Ji, Shenglu and Zhao, Jia and Lv, Yonghui and Wang, Jiayang and Sun, Daqing and Ding, Dan},
title = {A Fluorinated Supramolecular Self‐Assembled Peptide as Nanovaccine Adjuvant for Enhanced Cancer Vaccine Therapy},
journal = {Small Methods},
year = {2023},
volume = {7},
number = {5},
doi = {10.1002/smtd.202201409}
}
EUVIMED